Nielsen S D, Husemoen L L, Sørensen T U, Gram G J, Hansen J E
Laboratory for Infectious Diseases, H:S Hvidovre Hospital, Denmark.
J Hematother Stem Cell Res. 2000 Oct;9(5):695-701. doi: 10.1089/15258160050196731.
Before stem cell gene therapy can be considered for clinical applications, problems regarding cytokine prestimulation remain to be solved. In this study, a retroviral vector carrying the genes for the enhanced version of green fluorescent protein (EGFP) and neomycin resistance (neo(r)) was used for transduction of CD34+ cells. The effect of cytokine prestimulation on transduction efficiency and the population of uncommitted CD34+CD38- cells was determined. CD34+ cells harvested from umbilical cord blood were kept in suspension cultures and stimulated with combinations of the cytokines stem cell factor (SCF), FLT3 ligand, interleukin-3 (IL-3), IL-6, and IL-7 prior to transduction. Expression of the two genes was assessed by flow cytometry and determination of neomycin-resistant colonies in a selective colony-forming unit (CFU) assay, respectively. The neomycin resistance gene was expressed in a higher percentage of cells than the EGFP gene, but there seemed to be a positive correlation between expression of the two genes. The effect of cytokine prestimulation was therefore monitored using EGFP as marker for transduction. When SCF was compared to SCF in combination with more potent cytokines, highest transduction efficiency was found with SCF and IL-3 and IL-6 (5.05% +/- 0.80 versus 2.66% +/- 0.53 with SCF alone, p = 0.04). However, prestimulation with SCF in combination with IL-3 and IL-6 also reduced the percentage of CD34+ cells (p = 0.02). Then, prestimulation with SCF and FLT3 ligand was compared. Significant difference in transduction efficiency was not found. Interestingly, FLT3 ligand seemed to preserve the population of CD34+CD38- cells compared to SCF (16.56% +/- 2.02 versus 9.39% +/- 2.35, p = 0.03). In conclusion, prestimulation with potent cytokine combinations increased the transduction efficiency, but reduced the fraction of CD34+ cells. Importantly, the use of FLT3 ligand seemed to preserve the population of uncommitted cells.
在考虑将干细胞基因疗法应用于临床之前,细胞因子预刺激相关的问题仍有待解决。在本研究中,携带增强型绿色荧光蛋白(EGFP)基因和新霉素抗性(neo(r))基因的逆转录病毒载体用于转导CD34+细胞。测定了细胞因子预刺激对转导效率和未分化CD34+CD38-细胞群体的影响。从脐带血中采集的CD34+细胞保持悬浮培养,并在转导前用干细胞因子(SCF)、FLT3配体、白细胞介素-3(IL-3)、IL-6和IL-7等细胞因子组合进行刺激。分别通过流式细胞术和在选择性集落形成单位(CFU)测定中测定新霉素抗性集落来评估这两个基因的表达。新霉素抗性基因在细胞中的表达百分比高于EGFP基因,但这两个基因的表达之间似乎存在正相关。因此,以EGFP作为转导标记来监测细胞因子预刺激的效果。当将SCF与SCF联合更强效的细胞因子进行比较时,发现SCF与IL-3和IL-6联合时转导效率最高(分别为5.05%±0.80与单独使用SCF时的2.66%±0.53,p = 0.04)。然而,SCF与IL-3和IL-6联合预刺激也降低了CD34+细胞的百分比(p = 0.02)。然后,比较了SCF与FLT3配体的预刺激。未发现转导效率有显著差异。有趣的是,与SCF相比,FLT3配体似乎能保留CD34+CD38-细胞群体(分别为16.56%±2.02与9.39%±2.35,p = 0.03)。总之,强效细胞因子组合预刺激提高了转导效率,但降低了CD34+细胞的比例。重要的是,使用FLT3配体似乎能保留未分化细胞群体。